Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections
Overview
Stock Information
Nasdaq:
COCPPrice

Change

Mkt Cap

Volume

52 week Low/High

Day Low/High
